Medarex, Inc., a biopharmaceutical company, discovers, develops, and commercializes human antibody-based therapeutic products to treat cancer, inflammation, autoimmune disorders, and infectious diseases. The company applies its UltiMAb Human Antibody Development System, and product development and clinical manufacturing technologies to generate, support, and commercialize a range of fully human antibody product candidates for itself and its partners. As of December 31, 2006, it had 34 therapeutic product candidates derived from the company's technology in human clinical testing or with investigational new drug applications submitted for such trials. Its phase III clinical trial products include ipilimumab (MDX-010) for metastatic melanoma; golimumab (CNTO 148) for rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis; CNTO 1275 for psoriasis; zanolimumab (HuMax-CD4) for T-cell lymphomas; ofatumumab (HuMax-CD20) for chronic lymphocytic leukemia and follicular non-hodgkin's lymphoma; zalutumumab (HuMax-EGFr) for head and neck cancer; and CP-675,206 for metastatic melanoma. The company's phase II clinical trial products include Ipilimumab (MDX-010) for metastatic melanoma, prostate, breast, renal cell, and other cancers; MDX-066 and MDX-1388 for difficile disease; MDX-060 for lymphoma; CNTO 95 for cancer; and MDX-018 for inflammatory disease. It is also developing various phase I clinical trial products for ulcerative colitis, cancer, systemic lupus erythematosus, anthrax infection, autoimmune disease, psoriasis, idiopathic pulmonary fibrosis, diabetic nephropathy, and pancreatic cancer treatment. The company has partnership and/or collaboration agreements principally with Amgen, Inc.; BMS; Centocor; Eli Lilly and Company; Genmab A/S; ImClone Systems Incorporated; MedImmune, Inc.; Novartis Pharma AG; Novo Nordisk A/S; Pfizer, Inc.; and Kirin Brewing Co., Ltd. Medarex, Inc. was founded in 1987 and is headquartered in Princeton, New Jersey.